In a regulatory filing, Progyny (PGNY) disclosed that executive chairman David Schlanger bought 150K shares of Progyny common stock on December 26 at $14.68 per share. Following the release of the filing, in pre-market trading, shares of Progyny are higher by 5.4% to $15.50.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PGNY:
- Progyny downgraded to Neutral from Overweight at JPMorgan
- Progyny price target lowered to $17 from $30 at Barclays
- Progyny price target lowered to $19 from $24 at Jefferies
- Progyny price target lowered to $17 from $18 at Canaccord
- Progyny price target lowered to $21 from $22 at BofA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
